Ionising radiation and cancer risks: What have we learned from epidemiology?

被引:128
作者
Gilbert, Ethel S. [1 ]
机构
[1] NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA
关键词
Epidemiology; ionising radiation; cancer risks; dose-response; ATOMIC-BOMB SURVIVORS; X-RAY TREATMENT; LUNG-CANCER; BREAST-CANCER; THYROID-CANCER; CONTRALATERAL BREAST; CHILDHOOD-CANCER; SOLID CANCER; NUCLEAR INDUSTRY; TECHA RIVER;
D O I
10.1080/09553000902883836
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Purpose: Epidemiologic studies of persons exposed to ionising radiation offer a wealth of information on cancer risks in humans. The Life Span Study cohort of Japanese A-bomb survivors, a large cohort that includes all ages and both sexes with a wide range of well-characterised doses, is the primary resource for estimating carcinogenic risks from low linear energy transfer external exposure. Extensive data on persons exposed for therapeutic or diagnostic medical reasons offer the opportunity to study fractionated exposure, risks at high therapeutic doses, and risks of site-specific cancers in non-Japanese populations. Studies of persons exposed for occupational and environmental reasons allow a direct evaluation of exposure at low doses and dose rates, and also provide information on different types of radiation such as radon and iodine-131. This article summarises the findings from these studies with emphasis on studies with well-characterised doses. Conclusions: Epidemiologic studies provide the necessary data for quantifying cancer risks as a function of dose and for setting radiation protection standards. Leukaemia and most solid cancers have been linked with radiation. Most solid cancer data are reasonably well described by linear-dose response functions although there may be a downturn in risks at very high doses. Persons exposed early in life have especially high relative risks for many cancers, and radiation-related risk of solid cancers appears to persist throughout life.
引用
收藏
页码:467 / 482
页数:16
相关论文
共 50 条
  • [21] Anemia profiles in patients with lung cancer: What have we learned from the European Cancer Anaemia Survey (ECAS)?
    Kosmidis, P
    Krzakowski, M
    LUNG CANCER, 2005, 50 (03) : 401 - 412
  • [22] Recent progress in sepsis epidemiology – have we learned enough?
    Herwig Gerlach
    Didier Keh
    Critical Care, 7
  • [23] Risks from ionising radiation: an HPA viewpoint paper for Safegrounds
    Mobbs, S. F.
    Muirhead, C. R.
    Harrison, J. D.
    JOURNAL OF RADIOLOGICAL PROTECTION, 2011, 31 (03) : 289 - 307
  • [24] What Have We Learned From the Typhoid Fever Surveillance in Africa Program?
    Baker, Stephen
    Hombach, Joachim
    Marks, Florian
    CLINICAL INFECTIOUS DISEASES, 2016, 62 : S1 - S3
  • [25] NEO adjuvant chemotherapy in breast cancer: What have we learned so far
    Raut, Nirmal, V
    Chordiya, Nilesh
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2010, 31 (01) : 8 - 17
  • [26] From SARS to COVID-19: What lessons have we learned?
    Liu, Qin
    Xu, Kaiyuan
    Wang, Xiang
    Wang, Wenmei
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2020, 13 (11) : 1611 - 1618
  • [27] Current trends in estimating risk of cancer from exposure to low doses of ionising radiation
    Majer, Marija
    Knezevic, Zeljka
    Miljanic, Saveta
    ARHIV ZA HIGIJENU RADA I TOKSIKOLOGIJU-ARCHIVES OF INDUSTRIAL HYGIENE AND TOXICOLOGY, 2014, 65 (03): : 251 - 257
  • [28] Tegumentary leishmaniasis in the State of Amazonas: what have we learned and what do we need?
    de Oliveira Guerra, Jorge Augusto
    Maciel, Marcel Goncalves
    de Farias Guerra, Marcus Vinitius
    Talhari, Anette Chursciack
    Prestes, Suzane Ribeiro
    Fernandes, Marcos Antonio
    Da-Cruz, Alda Maria
    Martins, Alessandra
    Raposo Camara Coelho, Leila Ines de Aguiar
    Sierra Romero, Gustavo Adolfo
    Vale Barbosa, Maria das Gracas
    REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL, 2015, 48 : 12 - 19
  • [29] Clinical experience with ZarzioA® in Europe: what have we learned?
    Gascon, Pere
    Tesch, Hans
    Verpoort, Karl
    Rosati, Maria Sofia
    Salesi, Nello
    Agrawal, Samir
    Wilking, Nils
    Barker, Helen
    Muenzberg, Michael
    Turner, Matthew
    SUPPORTIVE CARE IN CANCER, 2013, 21 (10) : 2925 - 2932
  • [30] Candida auris: what have we learned so far?
    Corsi-Vasquez, Gabriela
    Ostrosky-Zeichner, Luis
    CURRENT OPINION IN INFECTIOUS DISEASES, 2019, 32 (06) : 559 - 564